These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 36208843)

  • 1. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
    J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
    Sacco M; Ribaldone DG; Saracco GM
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.
    Tsai PC; Huang CF; Yeh ML; Hsieh MH; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Chen CY; Huang JF; Dai CY; Chung WL; Bair MJ; Yu ML;
    Clin Mol Hepatol; 2024 Jul; 30(3):468-486. PubMed ID: 38637957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.
    Chang CW; Hsu WF; Tseng KC; Chen CY; Cheng PN; Hung CH; Lo CC; Bair MJ; Chen CH; Lee PL; Lin CY; Kuo HT; Chen CT; Yang CC; Huang JF; Tai CM; Hu JT; Lin CL; Su WW; Tsai WL; Huang YH; Cheng CY; Lin CL; Wang CC; Yang SS; Mo LR; Chen GY; Chang CC; Wang SJ; Huang CS; Hsieh TY; Lin CW; Lee TH; Chong LW; Huang CW; Chang SN; Tsai MC; Hsu SJ; Kao JH; Liu CJ; Liu CH; Lin HC; Tsai PC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Peng CY
    Dig Dis Sci; 2024 Sep; 69(9):3501-3512. PubMed ID: 38965159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
    Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
    Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients.
    Ma L; Liu J; Wang W; Yang F; Li P; Cai S; Zhou X; Chen X; Zhuang X; Zhang H; Cao G
    Future Oncol; 2020 Apr; 16(11):675-686. PubMed ID: 32223423
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
    Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.
    Huang CF; Yeh ML; Huang CY; Tsai PC; Ko YM; Chen KY; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
    Medicine (Baltimore); 2016 Jul; 95(27):e4157. PubMed ID: 27399135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.
    Lv GJ; Ji D; Yu L; Chen HY; Chen J; He M; Wang WC; Wang HB; Tsang C; Wang J; Yu ML; Lau G;
    Hepatol Int; 2024 Oct; 18(5):1459-1471. PubMed ID: 38965190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.